Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.7012
+0.03905.89%
Post-market: 0.70390.0027+0.39%17:14 EDT
Volume:5.91M
Turnover:4.16M
Market Cap:194.93M
PE:-1.41
High:0.7300
Open:0.6630
Low:0.6601
Close:0.6622
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.58
T/O Rate:2.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:6.24
PE(LYR):-2.72

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte

Reuters
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Humacyte prices 47,619,048-share follow-on offering at $1.05 each to raise $50 million

Reuters
·
Jun 11

Humacyte - Prices Public Offering of 47.62 Mln Shares at $1.05 per Share

THOMSON REUTERS
·
Jun 11

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire
·
Jun 11

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

Dow Jones
·
Jun 11

Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jun 11

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

MT Newswires Live
·
Jun 11

BRIEF-Humacyte, Inc. Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 11

Humacyte announces V012 study of ATEV meets primary endpoint

TIPRANKS
·
Jun 11

Humacyte announces common stock offering, no amount given

TIPRANKS
·
Jun 11

Humacyte launches underwritten follow-on common stock offering

Reuters
·
Jun 11

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jun 11

Humacyte - to Use Net Proceeds for Symvess Commercialization and Pipeline Development

THOMSON REUTERS
·
Jun 11

Humacyte ATEV beats AV fistula on catheter-free days in interim Phase 3 V012 trial in female dialysis patients

Reuters
·
Jun 11

Humacyte Atev Met Superiority Primary Endpoint Compared to Standard of Care Av Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

THOMSON REUTERS
·
Jun 11

Humacyte - Study Enrollment to Terminate After Meeting Primary Endpoint

THOMSON REUTERS
·
Jun 11

Humacyte - to File Supplemental Bla With FDA in Second Half of 2026

THOMSON REUTERS
·
Jun 11

Humacyte shareholders approve increase in authorized common shares to 550 million

Reuters
·
Jun 10

Humacyte Price Target Maintained With a $2.00/Share by BTIG

Dow Jones
·
Jun 08